ENTITY
Lupin Ltd

Lupin Ltd (LPC IN)

244
Analysis
Health Care • India
Lupin Limited manufactures bulk actives and formulations. The principal bulk actives manufactured by it include Rifampicin, Pyrazinamide, Ethambutol (anti-TB), Cephalosporins (anti-infectives) and cardiovasculars. The company also possesses competencies in phytomedicines, in which medicines are made out of plant and herbal resources supported by the discipline of modern medicine.
more
•03 Dec 2024 07:42•Broker

Axis Top Picks for the Month of December 2024

Axis Top Picks Basket delivered a return of 10.9% in the last six months against the 7.1% returns posted by Nifty 50 over the same period.

Logo
434 Views
Share
•24 Nov 2024 07:30

APAC Healthcare Weekly (Nov 24)- Samsung Biologics, Celltrion, Takeda, Kyowa Kirin, Astellas Pharma

​Samsung Biologics secures new manufacturing deals, Celltrion is acquiring iQone Healthcare, Takeda launches colorectal cancer drug in Japan, and...

Logo
1.1k Views
Share
•19 Nov 2024 20:45•Broker

Top Conviction Ideas – “Pharmaceutical & Hospitals”

The pharmaceutical universe under our coverage reported Q2FY25 growth of 10.2% year-on-year (YoY) and 1.7% quarteron-quarter (QoQ), driven by...

Logo
298 Views
Share
bullish•Lupin Ltd
•11 Nov 2024 23:14•Broker

LUPIN Ltd - Steady Outlook on Product Development; Maintain ADD

eported revenue grew by 12.6% YoY, led by the India business, which grew by 18.8% YoY, and the Asia-Pacific business, which grew by 30% YoY.

Logo
205 Views
Share
bullish•Lupin Ltd
•05 Nov 2024 06:51•Broker

Lupin: US and India on Steady Footing, Upgrade to ADD

We upgrade Lupin (LPC) to ADD from REDUCE with a revised TP of INR 2,440 (31x Q3FY27E, up from INR 1,950 at 28x Q1FY27E)

Logo
289 Views
Share
x